Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Altor BioScience begins development of ALT-803 for multiple myeloma

Nov. 5, 2014

arGEN-X files IND to begin study of ARGX-110 in Waldenstrom's macroglobulinemia

Nov. 4, 2014

Glioma candidate pritumumab receives U.S. orphan drug designation

Nov. 3, 2014

Kurume University discloses new cancer antigen peptide vaccines

Oct. 29, 2014

Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG

Oct. 28, 2014

Medivation licenses anti-PD-1 antibody pidilizumab from CureTech

Oct. 24, 2014

EMA grants orphan drug designation to isactuzumab govitecan

Oct. 21, 2014

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Oct. 16, 2014

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

Oct. 16, 2014

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Oct. 15, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...